Sugi Predict

Sugi Predict / Compounds / SCHEMBL132926

SCHEMBL132926

SCHEMBL132926

Nc1nc2[nH]cnc2c(=O)n1C1O[C@H](CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 1/20 0.54
▸ HSPA5 P11021 2/20 0.53
▸ HSPA8 P11142 2/20 0.53
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ LMNA P02545 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ MTOR P42345 2/20 0.47
▸ POLB P06746 1/20 0.47
▸ GMNN O75496 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ DNMT1 P26358 1/20 0.47
▸ THPO P40225 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ HBB P68871 1/20 0.47
▸ PMP22 Q01453 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8789685 1.00 PNP (0.54) PNPHSPA5HSPA8MEN1KMT2A
SCHEMBL2185987 1.00 PNP (0.54) PNPHSPA5HSPA8MEN1KMT2A
SCHEMBL10661591 1.00 PNP (0.54) PNPHSPA5HSPA8MEN1KMT2A
SCHEMBL10814753 1.00 PNP (0.54) PNPHSPA5HSPA8MEN1KMT2A
SCHEMBL10496354 1.00 PNP (0.54) PNPHSPA5HSPA8MEN1KMT2A
SCHEMBL10814776 1.00 PNP (0.54) PNPHSPA5HSPA8MEN1KMT2A
SCHEMBL375987 1.00 PNP (0.54) PNPHSPA5HSPA8MEN1KMT2A
SCHEMBL132928 1.00 PNP (0.54) PNPHSPA5HSPA8MEN1KMT2A
SCHEMBL7948397 1.00 PNP (0.54) PNPHSPA5HSPA8MEN1KMT2A
Phosphoric Acid SCHEMBL7200240 0.96 PNP (0.50) PNPHSPA5HSPA8MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116298235-A Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof 哈尔滨医科大学 2023-06-23 — — CN claimed
US-20120093729-A1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS, INC. (US) 2012-04-19 — — US claimed
EP-1724276-A1 Novel phosphorus-containing prodrugs Metabasis Therapeutics, Inc. (US) 2006-11-22 — — EP claimed
WO-2005090370-A1 PHARMACOLOGICALLY ACTIVE AGENTS CONTAINING ESTERIFIED PHOSPHONATES AND METHODS FOR USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-09-29 — — WO claimed
WO-2005079849-A2 COMPOUNDS FOR ENHANCED CANCER THERAPY ZGENE A/S (DK) 2005-09-01 — — WO claimed
US-20020052345-A1 Novel prodrugs for phosphorus-containing compounds METABASIS THERAPEUTICS, INC. 2002-05-02 — — US claimed
EP-1165570-A2 NOVEL PHOSPHORUS-CONTAINING PRODRUGS Metabasis Therapeutics, Inc. (US) 2002-01-02 — — EP claimed
US-6312662-B1 CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 METABASIS THERAPEUTICS, INC. 2001-11-06 — — US claimed
WO-2000052015-A2 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS, INC. (US) 2000-09-08 — — WO claimed
JP-58081794-A — — None — — JP disclosed
US-20250166176-A1 METHODS AND MATERIALS FOR IMAGING ADIPOSE TISSUE CELLSIGHT TECHNOLOGIES INC. (US) 2025-05-22 — — US disclosed
WO-2025090773-A1 ASSESSMENT OF SYSTEMIC IMMUNITY USING [F18]F-Ara-G IN POSITRON EMISSION TOMOGRAPHY CELLSIGHT TECHNOLOGIES INC. (US) 2025-05-01 — — WO disclosed
EP-4489799-A2 METHODS AND MATERIALS FOR IMAGING ADIPOSE TISSUE Cellsight Technologies Inc. (US) 2025-01-15 — — EP disclosed
US-11845933-B2 Structure-guided chemical modification of guide RNA and its applications MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-12-19 — — US disclosed
EP-0604409-A4 COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION. ISIS PHARMACEUTICALS INC (US) 1996-06-12 — — EP disclosed
EP-0604409-A1 COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 1994-07-06 — — EP disclosed
EP-0549615-A1 SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 1993-07-07 — — EP disclosed
WO-1992003568-A1 SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 1992-03-05 — — WO disclosed
WO-1991010671-A1 COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 1991-07-25 — — WO disclosed
JP-S5881794-A PREPARATION OF 9-BETA-D-ARABINOFURANOSYLGUANINE YAMASA SHOYU CO LTD 1983-05-17 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845933-B2 Structure-guided chemical modification of guide RNA and its applications ADAR, ZFR, NSUN2 PNP 992/4885HSPA5 3901/4885HSPA8 1726/4885
US-20020052345-A1 Novel prodrugs for phosphorus-containing compounds CCRL2, CCR4, ALK PNP 159/4885HSPA5 4737/4885HSPA8 4743/4885
US-20120093729-A1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS PYGL, ALPI, SLC10A1 PNP 14/4885HSPA5 2607/4885HSPA8 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.